Long-term continuous terlipressin infusion in cirrhotic patients with hepatorenal syndrome or refractory ascites awaiting liver transplantation is associated with an increase in plasma sodium

Ítems similars

• Continuous terlipressin infusion is associated with improved diet intake and muscle strength in patients awaiting liver transplant
  per: Chapman, Brooke, et al.
  Publicat: (2019)
• Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites
  per: Jasmohan S. Bajaj, et al.
  Publicat: (2022-01-01)
• Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence
  per: Bai, Zhaohui, et al.
  Publicat: (2020)
• An investigation of reconstituted terlipressin infusion stability for use in hepatorenal syndrome
  per: Bui, Thi Ngoc Nhieu, et al.
  Publicat: (2020)
• Rebound hypotension following terlipressin bolus infusion can be prevented by continuous low-dose infusion of terlipressin
  per: Lange, M, et al.
  Publicat: (2007)